Young people with early psychosis may not require antipsychotic medications to recover

June 17, 2020

Researchers at Orygen have found that some young people with early stage first episode psychosis (FEP) can experience reduced symptoms and improve functioning without antipsychotic medication when they are provided with psychological interventions and comprehensive case management.

The Staged Treatment and Acceptability Guidelines in Early Psychosis (STAGES) study compared two groups of young people, aged 15 - 25 years, presenting with FEP to a specialist early psychosis service.

Both groups received intensive psychosocial intervention, with one group also receiving low dose antipsychotic medication and the other receiving a placebo. The results have been published in Schizophrenia Bulletin Open.

The study found that the addition of antipsychotic medication to intensive psychosocial intervention did not lead to superior outcomes in symptoms and functioning within the first six months, suggesting that antipsychotic medication may not be needed early in the course of illness for all people within the spectrum of psychosis.

Orygen researcher Dr Shona Francey, who led the study, said the team wanted to investigate whether medication was an essential part of treatment for young people with early stage FEP.

"For a significant number of young people, it is. But, I think some young people can recover, at least initially, from their psychosis without medication," she said.

Current practice recommends anti-psychotic medication be taken from the outset of psychotic illness in order to achieve rapid recovery and improvement of psychotic symptoms.

However, Dr Francey said, in reality, a lot of people vote with their feet and don't take their medication for a variety of reasons.

"Medications can have heavy-duty side effects for young people, including weight gain which is a significant issue that young people are concerned about. There are also various sexual and other physical side effects that young people on medication have to contend with."

Dr Francey said that not all young people could delay their antipsychotic medication. "For many young people with early stage FEP, medication is an essential part of their treatment plan. But, for those young people who do not want medication, psychological interventions and comprehensive case management could be a feasible model of treatment.

"What the findings of this research tell us is that if a young person is reluctant to take medication for FEP, a period of intensive psychosocial treatments could be offered as an alternative," Dr Francey said.

She said a larger trial would be required to investigate whether antipsychotic-free treatment could be recommended for particular groups of young people with FEP.

"Young people currently using medication as part of their supervised treatment should continue to do so under the direction of their doctor," Dr Francey said.
-end-
This research was supported by funding from the National Health and Medical Research Council and Janssen-Cilag.

Orygen

Related Psychosis Articles from Brightsurf:

Unravelling the origins of autoimmune psychosis
Anti-NMDAR encephalitis is an autoimmune brain illness that is often mistaken by a psychiatric disorder since it causes psychoses and other behaviour alterations.

Targeted treatment for depression could benefit patients with psychosis
Patients with early onset psychosis may benefit from treatment for depression, including with anti-depressants alongside other medication, new research shows.

Pimavanserin reduced symptoms of dementia-related psychosis in phase 3 trial
New data presented at the Alzheimer's Association International Conference indicates that pimavanserin leads to a robust reduction in the severity of psychosis symptoms during the 12 week open-label phase of the study, regardless of the underlying dementia subtype or the severity of participants' dementia.

Young people with early psychosis may not require antipsychotic medications to recover
Researchers at Orygen have found that some young people with early stage first episode psychosis (FEP) can experience reduced symptoms and improve functioning without antipsychotic medication when they are provided with psychological interventions and comprehensive case management.

NMDA receptors may link psychosis and sleep deficits
Sofya Kulikova, a researcher at HSE University in Perm, is part of an international research team that has discovered potential mechanisms that explain the sleep spindle deficit in electroencephalograms (EEG) of people with schizophrenia.

Almost half of all postpartum psychosis are isolated cases
A new research result from iPSYCH shows that 40% of the women who suffer a psychosis after giving birth -- known as postpartum psychosis - do not subsequently become ill again.

Thirty risk factors found during and after pregnancy for children developing psychosis
More than 30 significant risk factors have been identified for the development of psychotic disorders in offspring in research led by the NIHR Maudsley BRC.

A new window into psychosis
A recent study in mice led a team of researchers in Japan to believe that psychosis may be caused by problems with specialized nerve cells deep within the brain, as well as a certain kind of learning behavior.

New insight into how cannabidiol takes effect in the brains of people with psychosis
Researchers from King's College London have shown that cannabidiol (CBD) alters the brain activity in people with psychosis during memory tasks, making it more similar to the activation seen in people without psychosis during the same tasks.

Study finds 'cluster of disadvantage' behind BAME psychosis rates
Excess psychosis diagnoses amongst black and South Asian men in deprived urban areas could reflect a cluster of disadvantage in specific places, rather than individual experiences of deprivation alone, a study led by Queen Mary University of London researchers concludes.

Read More: Psychosis News and Psychosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.